SERNOVA WKN: A0LBCR ISIN: CA81732W1041 Kürzel: SVA Forum: Aktien Thema: Hauptdiskussion

Der Nepper, Schlepper & Bauernfänger L U S C H E hat schon die nächste 🇨🇦🍟 Schrottaktie am Start.

Das hast du wahrscheinlich recht 👍🏻

Jedes Jahr derselbe Müll. Fällt kaum jemand noch drauf rein. Kanadabude 👀

https://www.nature.com/articles/d43747-024-00127-2?utm_campaign=topic_ipsccelltherapy_2024&utm_content=318190851&utm_medium=social&utm_source=linkedin&hss_channel=lcp-15720

Under new leadership, Sernova is committed to transparency and fostering engagement with its shareholders and will host a virtual Town Hall for investors on Friday, December 13, at 10:00am ET. The event will feature the company’s recently appointed CEO, Jonathan Rigby, who will discuss recent developments and Sernova’s strategic plans to create long-term value for shareholders. This will be followed by an open forum for questions and answers. The webcast registration link will soon be available in the Investor section of the company’s website at https://sernova.com/. In addition, the Company is holding an Annual General and Special Meeting of Shareholders on January 7, 2025. The Management Information Circular for the meeting will be available on the Company’s website on December 6, 2024.

On November 12, at the Riyadh Global Medical Biotechnology Summit, Sernova entered into a non-binding letter of intent with HealthGena and GOLDTRACK Ventures regarding ‘Project REEM Ventures’ to explore opportunities for product development and commercialization initiatives in the Kingdom of Saudi Arabia to address the growing incidence of type 1 diabetes. ‘Project REEM Ventures’ is a collaboration initiative between Sernova, HealthGena and GOLDTRACK Ventures. HealthGena is a Riyadh-based business accelerator with a focus on biotechnology innovation. GOLDTRACK Ventures is a German-regulated venture capital manager based in Leipzig, Germany, specializing in Life Science investments. A definitive agreement has not been entered into. Additionally, Sernova is honored to welcome Dr. Robert Gabbay who will serve in a clinical advisory role. Dr. Gabbay brings a significant wealth of expertise in diabetes care and research, having most recently served as Chief Scientific and Medical Officer at the American Diabetes Association, and previously as Chief Medical Officer at the Joslin Diabetes Center, one of the world’s leading diabetes research organizations. His expertise will be instrumental as Sernova advances in clinical trial development and product innovation.

Signed Letter of Intent with ‘Project REEM Ventures’ for Product Development and Commercialization in the Kingdom of Saudi Arabia https://www.sernova.com/investor/?disclaimer=1#News_Releases

Das Ding ist tot, ausgeluscht, Pump & Dump. Deutsche Kohle abgefischt... viele haben hier Geld verloren. Und jetzt geht das mit anderen Pennystocks so weiter. Wer bei sowas investiert und Geld verliert, ist selber schuld. Leider macht Geldgier blind, denn Gier frisst Hirn. Verstehen viele leider nicht... oder erst, wenn es zu spät ist. Finger weg von solchen Aktien!

Hätte hier auch mal wie bei ATOS uns Spineway kurz hochgehen können 🥲😂

bei LifeScy events

Virtuelles Investoren-Event von Sernova am 13.12.24 um 10 Uhr AM

🍀🙏🤗

Die ersten ziehen die Reißleine vor der nächsten KE? Forschung kostet halt Geld. 💰😂🫣

Eigentlich schon noch… ✊🏼🍀 abwarten

Ich habe hier keine Hoffnung mehr.

Dann sagen wir’s mal so. Ich sehe schwarz für Sernova